CJC-1295 No DAC 5mg + Ipamorelin 5mg Research Blend Australia
CJC-1295 No DAC 5mg + Ipamorelin 5mg is a fixed-ratio dual-peptide research blend supplied in one vial with 10mg total nominal peptide content. The blend contains 5mg nominal CJC-1295 No DAC and 5mg nominal Ipamorelin, giving a 1:1 ratio by labelled mass.
Australian Peptide maintains this 10mg blend as a separate product record from the existing 20mg CJC-1295 No DAC + Ipamorelin blend so researchers can distinguish the vial strength, formulation, SKU, batch identifier and applicable analytical documentation.
Looking to buy CJC-1295 No DAC + Ipamorelin in Australia for laboratory research? This listing is supplied from Australia for lawful laboratory, analytical and in-vitro research only. It is not intended for human, veterinary, therapeutic, cosmetic or personal use.
Key Features
- 10mg total nominal peptide content
- CJC-1295 No DAC 5mg + Ipamorelin 5mg
- Fixed 1:1 blend by labelled mass
- Lyophilised research material
- Separate strength-specific product record
- Batch identification and traceability
- Batch-specific Janoshik COA required before sale
- Australian dispatch
Product Specifications
Product Name: CJC-1295 No DAC + Ipamorelin Research Blend
CJC-1295 No DAC: 5mg nominal content
Ipamorelin: 5mg nominal content
Total Nominal Content: 10mg
Nominal Ratio: 1:1
Quantity: 1 vial
Physical Form: Lyophilised powder
Research Category: Dual-peptide GHRH / growth-hormone-secretagogue research blend
Country of Dispatch: Australia
Research Profile and Nomenclature
CJC-1295 No DAC is a catalogue term commonly used in the research-peptide market for the shorter-acting Modified GRF (1-29)-type GHRH analogue. It should not be treated as equivalent to long-acting CJC-1295 with DAC. The two materials differ in molecular design and pharmacokinetic behaviour, so literature involving the DAC-containing analogue should not automatically be attributed to the No-DAC material.
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue investigated through the ghrelin / growth-hormone-secretagogue receptor pathway. In research settings, CJC-1295 No DAC and Ipamorelin are often grouped because they engage different receptor systems associated with growth-hormone signalling.
The important analytical distinction is that this vial is not one 10mg peptide. It is a mixture containing two distinct peptide materials. Identity, purity and quantity therefore need to be considered at component level as well as at the blend level.
For deeper scientific background, see What Is CJC-1295 No DAC?, What Is Ipamorelin? and our guide to the CJC-1295 No DAC + Ipamorelin research blend.
What 5mg + 5mg Means
The 5mg + 5mg designation identifies the nominal quantity of each component in the vial. It does not by itself establish chromatographic purity, solution concentration, biological activity or a universal laboratory preparation method.
Researchers comparing vial strengths should distinguish mass from concentration. For a general explanation, see What Does mg Mean on a Peptide Vial? and the Peptide Concentration Guide.
Certificate of Analysis and Batch Verification
Australian Peptide only activates research peptide listings for sale when the saleable batch can be matched to batch-specific analytical documentation. For this blend, the Certificate of Analysis should correspond to the exact CJC-1295 No DAC + Ipamorelin formulation and batch being supplied rather than to a generic CJC-1295 or Ipamorelin record.
Researchers should match the batch identifier on the supplied vial with the applicable Janoshik record before documenting analytical work. Current batch documentation can be reviewed through the COA Library. Learn more about our standards through Quality Assurance and Certificate of Analysis Explained.
Storage and Laboratory Handling
Peptide stability depends on material identity, packaging, temperature, moisture exposure and the validated method being used. Keep sealed lyophilised research material protected from unnecessary heat, light and moisture and follow the applicable batch or laboratory documentation. Do not assume that one storage period or solution condition is universal across different peptides or blends.
For general research handling principles, see Laboratory Storage of Research Peptides.
Related Research Products
Researchers who require a larger fixed-ratio presentation can compare the CJC-1295 No DAC 10mg + Ipamorelin 10mg Research Blend. Researchers who need to vary the two components independently can review CJC-1295 No DAC 10mg and Ipamorelin 10mg as separate materials.
For concentration arithmetic used in laboratory planning, Australian Peptide also provides a Peptide Reconstitution Calculator as a mathematical research reference tool.
Frequently Asked Questions
Where can laboratories buy CJC-1295 No DAC + Ipamorelin 10mg in Australia?
Australian Peptide supplies this 5mg + 5mg research blend online in Australia for lawful laboratory and analytical research, with Australian dispatch and batch-specific documentation required for the active sale batch.
Is the vial 10mg total?
Yes. The labelled formulation is 5mg CJC-1295 No DAC plus 5mg Ipamorelin, for 10mg total nominal peptide content.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
No. CJC-1295 with DAC is a distinct long-acting analogue. The No-DAC catalogue term is commonly associated with Modified GRF (1-29)-type material and should be treated separately in research records.
Why use a fixed-ratio blend instead of separate vials?
A fixed-ratio blend provides both materials in one defined starting formulation. Separate vials are more appropriate where researchers need to vary the two components independently.
Does evidence for either individual peptide prove the behaviour of the blend?
No. Component-level evidence and evidence for the exact co-formulated blend are different questions. Findings for either peptide alone should not automatically be attributed to this mixed preparation.
Is this product intended for human use?
No. This product is supplied strictly for lawful laboratory, analytical and in-vitro research. No dosing, administration or therapeutic guidance is provided.
Australian Peptide Research Standards
Australian Peptide supplies research materials with an emphasis on clear product identification, batch traceability and accessible analytical documentation. Active peptide batches are required to have batch-specific documentation that matches the material being supplied.
- Australian dispatch
- Batch-specific analytical documentation
- Janoshik Certificate of Analysis required for the active sale batch
- COA Library access and batch traceability
- Research-focused product information
- Price Match Guarantee for eligible comparable Australian listings
Current retail promotions, multi-vial savings, complimentary-vial eligibility and shipping offers are applied according to the terms displayed on the website and at checkout.
